Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596768 | 0.91 | ORAI1 (0.44) | LIPGENPP2LIPEORAI1ORAI2 | |
| SCHEMBL520432 | 0.84 | LIPG (0.50) | LIPGENPP2LIPEORAI1ORAI2 | |
| SCHEMBL29504613 | 0.84 | LIPG (0.50) | LIPGENPP2LIPEORAI1ORAI2 | |
| SCHEMBL24107427 | 0.84 | LIPG (0.43) | LIPGENPP2LIPEORAI1ORAI2 | |
| SCHEMBL27933364 | 0.82 | IDO1 (0.39) | IDO1 | |
| SCHEMBL2058938 | 0.81 | ENPP2 (0.31) | LIPGENPP2ORAI1ORAI2ORAI3 | |
| SCHEMBL29952834 | 0.81 | LIPG (0.52) | LIPGENPP2LIPEORAI1ORAI2 | |
| SCHEMBL12544470 | 0.81 | LIPG (0.52) | LIPGENPP2LIPEORAI1ORAI2 | |
| SCHEMBL2058939 | 0.79 | — | — | |
| SCHEMBL27752424 | 0.77 | IDO1 (0.40) | ENPP2LIPEORAI1ORAI2ORAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066787-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9572823-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9566290-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566289-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9549938-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160228463-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160206638-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160184334-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160151399-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9353133-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2044091-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | Anacor Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1638578-A4 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-7465836-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2007146965-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | ANACOR PHARMACEUTICALS INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1638578-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005013892-A9 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS INC (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2005013892-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206638-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | LIPG 4818/4885ENPP2 2150/4885LIPE 4735/4885 |
| US-20170066787-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | LIPG 4818/4885ENPP2 2150/4885LIPE 4735/4885 |
| US-20160151399-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | LIPG 4818/4885ENPP2 2150/4885LIPE 4735/4885 |
| US-20160228463-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | LIPG 4818/4885ENPP2 2150/4885LIPE 4735/4885 |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | BPGM, HMBS, PPIP5K2 | LIPG 305/4885ENPP2 350/4885LIPE 802/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | LIPG 4818/4885ENPP2 2150/4885LIPE 4735/4885 |
| US-20160184334-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | LIPG 4818/4885ENPP2 2150/4885LIPE 4735/4885 |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | BTD, GAA, GBA3 | LIPG 161/4885ENPP2 646/4885LIPE 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.